13,591 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Crestline Management LP

Crestline Management LP purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 13,591 shares of the medical device company's stock, valued at approximately $1,057,000.

Several other hedge funds also recently added to or reduced their stakes in DXCM. Capitolis Liquid Global Markets LLC acquired a new stake in shares of DexCom during the fourth quarter worth $13,610,000. Cetera Investment Advisers grew its position in DexCom by 16.8% during the 4th quarter. Cetera Investment Advisers now owns 72,182 shares of the medical device company's stock worth $5,614,000 after purchasing an additional 10,385 shares during the period. Brevan Howard Capital Management LP purchased a new stake in DexCom in the 4th quarter worth approximately $261,000. Captrust Financial Advisors increased its holdings in shares of DexCom by 22.1% during the 4th quarter. Captrust Financial Advisors now owns 28,152 shares of the medical device company's stock valued at $2,189,000 after purchasing an additional 5,101 shares in the last quarter. Finally, Caxton Associates LP purchased a new position in shares of DexCom during the 4th quarter valued at approximately $23,331,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is owned by company insiders.

DexCom Stock Up 0.4%

Shares of DXCM stock traded up $0.38 on Monday, reaching $85.05. 4,029,833 shares of the stock were exchanged, compared to its average volume of 4,330,484. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $132.26. The company has a market capitalization of $33.35 billion, a price-to-earnings ratio of 59.48, a PEG ratio of 2.30 and a beta of 1.43. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The business's 50 day moving average price is $71.08 and its 200 day moving average price is $77.22.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. The company's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 EPS. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Barclays boosted their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Finally, Piper Sandler reduced their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.